PDF(Pubmed)
Abstract：
BACKGROUND: Diabetic eyes suffer from variety of complications including macular edema. Cataract surgery is the most commonly done procedure throughout the world and majority would be diabetics. As pseudophakic-cystoid macular edema (CME) is a known complication following cataract surgery, our study concentrated on finding the role of prophylactic topical nonsteroidal anti-inflammatory drugs (NSAIDs) on change in total macular volume (TMV) postcataract surgery in diabetic eyes.
OBJECTIVE: To evaluate the role of NSAIDs on change in TMV postcataract surgery in diabetic eyes.
METHODS: Retrospective comparative study.
METHODS: Data were collected from the medical records department of our institute constituting diabetics undergoing cataract surgery from June-2021 to February-2022. Eighty diabetic eyes were divided into two groups: one group were given topical nepafenac drops and another who were not given. Demographic details, diabetic retinopathy stage, preoperative optical coherence tomography (OCT), and postoperative day (POD) 7, day 28, and 3 months OCT were collected. Statistical analysis was done to compare the change in TMV between both the groups.
METHODS: Student\'s t-test and Chi-squared/Fisher\'s exact test were employed to find statistically significant differences between the two groups using SPSS-22.0 software.
RESULTS: In our study, the mean age in the group with nepafenac was 60.93 ± 5.86 years and 31 (77.5%) had moderate nonproliferative diabetic retinopathy (NPDR), and in the group without nepafenac, the mean age was 58.53 ± 7.41 years and 30 (75%) had moderate NPDR. Majority of the individuals in the study group were known diabetic for 2-5 years. Change in TMV at POD 3 months among two groups was not statistically significant; P = 0.758 (P < 0.05-significant).
CONCLUSIONS: Our study concluded that topical-NSAIDs played no role in postoperative period following cataract surgery with respect to change in TMV in diabetic eyes. Thus, prophylactic usage of topical-NSAIDs can be a burden on patient as it has no role in prevention of pseudophakic-CME in those with the duration of diabetes mellitus <5 years and with mild-to-moderate NPDR.
OBJECTIVE: To evaluate the role of NSAIDs on change in TMV postcataract surgery in diabetic eyes.
METHODS: Retrospective comparative study.
METHODS: Data were collected from the medical records department of our institute constituting diabetics undergoing cataract surgery from June-2021 to February-2022. Eighty diabetic eyes were divided into two groups: one group were given topical nepafenac drops and another who were not given. Demographic details, diabetic retinopathy stage, preoperative optical coherence tomography (OCT), and postoperative day (POD) 7, day 28, and 3 months OCT were collected. Statistical analysis was done to compare the change in TMV between both the groups.
METHODS: Student\'s t-test and Chi-squared/Fisher\'s exact test were employed to find statistically significant differences between the two groups using SPSS-22.0 software.
RESULTS: In our study, the mean age in the group with nepafenac was 60.93 ± 5.86 years and 31 (77.5%) had moderate nonproliferative diabetic retinopathy (NPDR), and in the group without nepafenac, the mean age was 58.53 ± 7.41 years and 30 (75%) had moderate NPDR. Majority of the individuals in the study group were known diabetic for 2-5 years. Change in TMV at POD 3 months among two groups was not statistically significant; P = 0.758 (P < 0.05-significant).
CONCLUSIONS: Our study concluded that topical-NSAIDs played no role in postoperative period following cataract surgery with respect to change in TMV in diabetic eyes. Thus, prophylactic usage of topical-NSAIDs can be a burden on patient as it has no role in prevention of pseudophakic-CME in those with the duration of diabetes mellitus <5 years and with mild-to-moderate NPDR.
摘要：
背景：糖尿病眼患有各种并发症，包括黄斑水肿。白内障手术是世界上最常见的手术，大多数是糖尿病患者。由于假性晶状体囊样黄斑水肿（CME）是白内障手术后的已知并发症，我们的研究集中于发现预防性外用非甾体类抗炎药(NSAIDs)对糖尿病眼白内障手术后黄斑总体积(TMV)变化的作用.
目的：评价非甾体抗炎药在糖尿病眼白内障术后TMV变化中的作用。
方法：回顾性对比研究。
方法：数据来自我们研究所的医疗记录部门，包括2021年6月至2022年2月接受白内障手术的糖尿病患者。将80只糖尿病眼分为两组：一组给予局部用奈帕芬胺滴剂，另一组不给予。人口统计细节，糖尿病视网膜病变阶段，术前光学相干断层扫描（OCT），收集术后第7天、第28天和第3个月的OCT。进行统计分析以比较两组之间TMV的变化。
方法：采用学生t检验和卡方/Fisher精确检验，使用SPSS-22.0软件发现两组之间的统计学差异。
结果：在我们的研究中，奈帕芬胺组的平均年龄为60.93±5.86岁，31岁（77.5%）患有中度非增生性糖尿病视网膜病变（NPDR），在没有奈帕芬胺的组中，平均年龄为58.53±7.41岁,30岁(75%)患有中度NPDR.研究组中的大多数个体已知为2-5年的糖尿病患者。两组在POD3个月时TMV的变化无统计学意义；P=0.758（P<0.05-显着）。
结论：我们的研究得出结论，在白内障手术后，局部NSAIDs在糖尿病眼TMV变化方面没有作用。因此，预防性使用NSAIDs可能会给患者带来负担,因为在糖尿病病程<5年和轻度至中度NPDR的患者中,NSAIDs对预防假晶状体-CME没有作用.
目的：评价非甾体抗炎药在糖尿病眼白内障术后TMV变化中的作用。
方法：回顾性对比研究。
方法：数据来自我们研究所的医疗记录部门，包括2021年6月至2022年2月接受白内障手术的糖尿病患者。将80只糖尿病眼分为两组：一组给予局部用奈帕芬胺滴剂，另一组不给予。人口统计细节，糖尿病视网膜病变阶段，术前光学相干断层扫描（OCT），收集术后第7天、第28天和第3个月的OCT。进行统计分析以比较两组之间TMV的变化。
方法：采用学生t检验和卡方/Fisher精确检验，使用SPSS-22.0软件发现两组之间的统计学差异。
结果：在我们的研究中，奈帕芬胺组的平均年龄为60.93±5.86岁，31岁（77.5%）患有中度非增生性糖尿病视网膜病变（NPDR），在没有奈帕芬胺的组中，平均年龄为58.53±7.41岁,30岁(75%)患有中度NPDR.研究组中的大多数个体已知为2-5年的糖尿病患者。两组在POD3个月时TMV的变化无统计学意义；P=0.758（P<0.05-显着）。
结论：我们的研究得出结论，在白内障手术后，局部NSAIDs在糖尿病眼TMV变化方面没有作用。因此，预防性使用NSAIDs可能会给患者带来负担,因为在糖尿病病程<5年和轻度至中度NPDR的患者中,NSAIDs对预防假晶状体-CME没有作用.
